Leap Therapeutics Inc (NASDAQ: LPTX)’s stock price has gone rise by 14.64 in comparison to its previous close of 2.80, however, the company has experienced a 7.00% increase in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-20 that Leap Therapeutics (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Is It Worth Investing in Leap Therapeutics Inc (NASDAQ: LPTX) Right Now?
The 36-month beta value for LPTX is also noteworthy at 0.57. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for LPTX is 23.43M, and at present, short sellers hold a 4.86% of that float. The average trading volume of LPTX on April 23, 2024 was 323.36K shares.
LPTX’s Market Performance
LPTX stock saw an increase of 7.00% in the past week, with a monthly gain of 25.88% and a quarterly increase of 5.59%. The volatility ratio for the week is 9.14%, and the volatility levels for the last 30 days are 13.07% for Leap Therapeutics Inc (LPTX). The simple moving average for the past 20 days is 14.80% for LPTX’s stock, with a 27.80% simple moving average for the past 200 days.
Analysts’ Opinion of LPTX
Many brokerage firms have already submitted their reports for LPTX stocks, with Mizuho repeating the rating for LPTX by listing it as a “Buy.” The predicted price for LPTX in the upcoming period, according to Mizuho is $6 based on the research report published on October 04, 2021 of the previous year 2021.
Robert W. Baird, on the other hand, stated in their research note that they expect to see LPTX reach a price target of $5. The rating they have provided for LPTX stocks is “Outperform” according to the report published on June 04th, 2021.
Piper Sandler gave a rating of “Overweight” to LPTX, setting the target price at $6 in the report published on June 29th of the previous year.
LPTX Trading at 15.77% from the 50-Day Moving Average
After a stumble in the market that brought LPTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.53% of loss for the given period.
Volatility was left at 13.07%, however, over the last 30 days, the volatility rate increased by 9.14%, as shares surge +27.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.82% lower at present.
During the last 5 trading sessions, LPTX rose by +7.00%, which changed the moving average for the period of 200-days by +1.10% in comparison to the 20-day moving average, which settled at $2.83. In addition, Leap Therapeutics Inc saw -22.56% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for LPTX
Current profitability levels for the company are sitting at:
- -137.29 for the present operating margin
- 0.33 for the gross margin
The net margin for Leap Therapeutics Inc stands at -127.05. The total capital return value is set at -1.45. Equity return is now at value -136.82, with -113.72 for asset returns.
Based on Leap Therapeutics Inc (LPTX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -167.0.
Currently, EBITDA for the company is -86.61 million with net debt to EBITDA at 0.84. When we switch over and look at the enterprise to sales, we see a ratio of 18.62. The receivables turnover for the company is 0.82for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.64.
Conclusion
In summary, Leap Therapeutics Inc (LPTX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
